RxDoctor Payments Data

John Strong, MD

Family Medicine · El Centro, CANPI 1043248719

Payments from drug & device makers

$6,162in general payments, 2019–2025

Across 246 payments — averaging $25.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$724
  • AstraZeneca$680
  • Novo Nordisk$465
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
  • Amgen$370
  • Merck$333
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$6,154100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,162 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$743,375
Medicare patients
1,429
Services billed
13,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$123,195
TrulicityDulaglutide94$103,422
FarxigaDapagliflozin Propanediol120$92,211
JardianceEmpagliflozin76$63,962
LinzessLinaclotide83$53,833
EliquisApixaban62$53,489
JanuviaSitagliptin Phosphate50$50,924
TradjentaLinagliptin65$46,497
RybelsusSemaglutide29$38,150
EntrestoSacubitril/Valsartan34$34,402
ProliaDenosumab17$28,958
MyrbetriqMirabegron42$28,110
MounjaroTirzepatide19$24,931
DapagliflozinDapagliflozin Propanediol30$24,274
XareltoRivaroxaban26$24,081

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$465$161,344163 claims
Lilly USA, LLCTrulicity, Mounjaro$141$128,353113 claims
AstraZenecaFarxiga, Breztri Aerosphere, Lokelma$680$120,161161 claims
Boehringer IngelheimJardiance, Tradjenta$99$110,459141 claims
AbbVieLinzess$100$53,83383 claims
PfizerEliquis$142$53,48962 claims
MerckJanuvia$333$50,92450 claims
NovartisEntresto$282$34,40234 claims
AmgenProlia$370$28,95817 claims
Astellas Pharma US IncMyrbetriq$100$28,11042 claims
Johnson & JohnsonXarelto$153$24,08126 claims
GSKTrelegy Ellipta, Breo Ellipta$724$20,15935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in El Centro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →